Premium
LiSa‐2, a novel human liposarcoma cell line with a high capacity for terminal adipose differentiation
Author(s) -
Wabitsch Martin,
Brüderlein Silke,
Melzner Ingo,
Braun Mike,
Mechtersheimer Gunhild,
Möller Peter
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/1097-0215(20001215)88:6<889::aid-ijc8>3.0.co;2-n
Subject(s) - adipocyte , adipose tissue , biology , cell culture , cellular differentiation , lipoprotein lipase , lipid droplet , endocrinology , medicine , microbiology and biotechnology , biochemistry , gene , genetics
LiSa‐2 is a stable cell line derived from a poorly differentiated, pleomorphic liposarcoma. In serum‐containing medium, LiSa‐2 cells are fibroblastoid and rapidly dividing. In a serum‐free, chemically defined culture medium containing physiological concentrations of insulin, triiodothyronine and cortisol, LiSa‐2 cells divide slower and, extensively storing fat, acquire adipocyte morphology. In contrast to fibroblastoid LiSa‐2 cells, these adipocyte‐like LiSa‐2 cells highly express transcripts for peroxisome proliferator‐activated receptor‐γ, lipoprotein lipase, fatty acid synthetase, hormone‐sensitive lipase, adipocyte most abundant gene transcript‐1, glycerol‐3‐phosphate‐dehydrogenase and the insulin‐sensitive glucose transporter‐4, all of which are specific for differentiated adipocytes. However, leptin mRNA expression was demonstrated only after preventing DNA methylation by incorporation of 5‐aza‐deoxycytidine into cellular DNA. Functionally, adipocyte‐like LiSa‐2 cells show increased insulin‐dependent glucose uptake and lipid synthesis and are sensitive to lipolytic agents. This cell line may serve as an in vitro model for studying the regulation of human liposarcoma differentiation and for screening drugs for induction of differentiation‐associated growth arrest in liposarcomas. Int. J. Cancer 88:889–894, 2000. © 2000 Wiley‐Liss, Inc.